Effect of Fixed‐Dose ACE‐Inhibitor/Calcium Channel Blocker Combination Therapy vs. ACE‐Inhibitor Monotherapy on Arterial Compliance in Hypertensive Patients With Type 2 Diabetes

• DOI: 10.1111/j.1520-037x.2005.3535.x
• Publication Date: 2007-02-02T18:26:35Z
• Authors: Nathaniel Winer; Amy Folker; Julie A. Murphy; Elena Hung; Mara Bard; Alexander Perkelvald; James R. Sowers; George L. Bakris
• Keywords: Calcium channel blocker; Amlodipine; Benazepril; Combination therapy; Essential hypertension

Assessment of vascular compliance may be a useful measurement the clinical effects antihypertensive treatment. Both angiotensin‐converting enzyme (ACE) inhibitors and calcium channel blockers are known to improve elasticity. A study was performed test hypothesis that combined therapy with an ACE inhibitor blocker would have additive benefits on at similar levels blood pressure (BP), as compared monotherapy inhibitor. This 12‐week, double‐blind substudy larger hypertension conducted in patients type 2 diabetes. Subjects (N=20) were randomized either fixed‐dose combination amlodipine besylate/benazepril HCl or enalapril monotherapy. BP, heart rate, large‐ small‐vessel compliance, systemic resistance, urinary microalbumin excretion assessed baseline after treatments similarly effective lowering reducing decreasing excretion. Improvement large‐vessel significantly greater among subjects who received ACE‐inhibitor/calcium (52%) those ACE‐inhibitor (32%; p <0.05). No significant change observed Greater improvement independent BP lowering.